DEGIRO Retailises European Online Brokerage With Zero Commission Trading on Top US and European Exchanges
18.11.2021 17:38:00 EET | Business Wire | Press release
Today, flatexDEGIRO (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest-growing pan-European retail online broker announced the introduction of zero commission trading at DEGIRO, starting as of 22 November 2021. DEGIRO customers across Europe will thereby be able to trade without any commission over 5,000 US equities directly on the leading US exchanges NASDAQ and NYSE. Additionally, in the most important growth markets, France, Spain, Portugal and Italy, as well as in Sweden and Denmark, they will trade all ETFs commission-free as well as equities on the respective local Tier 1 exchanges, including Euronext Paris, and Lisbon, NASDAQ Stockholm, Bolsa de Madrid and Borsa Italia.
For the very first time, European retail investors will be able to trade at zero commission without having to compromise on quality, service, security, product choice or place of execution. flatexDEGIRO leverages its technological edge, its financial strengths and the scale of its market-leading pan-European online brokerage business to make this unique offer. The attractiveness and quality of the offer is expected to lead to an increasing revenue base and additional economies of scale which, together with optimised monetisation, should strongly improve flatexDEGIRO's operating profitability.
Frank Niehage, CEO of flatexDEGIRO: "With 'DEGIRO goes zero', we are changing the face of online brokerage in Europe. DEGIRO provides the lowest prices in the market with full cost transparency and no compromise on quality. We are now not only leading in platform and product but also in price. This will further increase the attractiveness of long-term investing and trading on our platform for millions of Europeans. No one interested in online brokerage should ever again feel the need to trade with brokers who supposedly charge no commissions but offer only intransparent and low-quality alternatives."
Muhamad Chahrour, CEO of DEGIRO and CFO of flatexDEGIRO: "It's as simple as that: for years, many so-called 'neo-brokers' claimed to offer zero commission trading - but at what costs? Clients were attracted to trade either highly risky CFDs or with market makers having intransparent product-pricing and scrutinised payments for order flow. No retail customer should ever again accept this specious trade-off. We promised to retailise capital market access - this is exactly what we now do with this revolutionary step. DEGIRO launches the first fair and most transparent zero commission retail brokerage, not relying on any payment for order flow."
Complex variable fee structures for external cost such as exchange fees and regulatory costs will be eliminated by a transparent and simple flat handling fee of as little as 50 Cents per transaction. DEGIRO also supports the best access to international equity markets with transparent and outstanding FX services and fees, including one of the lowest FX fees in the whole financial industry of just 0.25%.
About flatexDEGIRO AG
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates one of the leading and fastest growing online brokerage businesses in Europe, executing millions of paperless securities transactions per annum. B2C customers in 18 European countries are serviced via the flatex and DEGIRO brands and offered a wide range of independent products at competitive pricing, based on a modern, in-house state-of-the-art technology.
With more than 1.25 million customers and over 75 million securities transactions in 2020, flatexDEGIRO is the largest retail online broker in Europe. In a time of bank consolidation, low interest rates and digitalization, the flatexDEGIRO Group is ideally positioned for further growth. Within the next five years, flatexDEGIRO aims to grow its customer base to 7-8 million customers, settling 250-350 million transactions per year - even in years with low volatility.
More information via https://www.flatexdegiro.com/en
|
Language: |
English |
|
|
Company: |
flatexDEGIRO AG |
|
|
Rotfeder-Ring 7 |
||
|
60327 Frankfurt / Main |
||
|
Germany |
||
|
Phone: |
+49 (0) 69 450001 0 |
|
|
E-mail: |
||
|
Internet: |
||
|
ISIN: |
DE000FTG1111 |
|
|
WKN: |
FTG111 |
|
|
Indices: |
SDAX |
|
|
Listed: |
Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange |
|
|
EQS News ID: |
1250311 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005880/en/
Contact information
Achim Schreck Tel. +49 (0) 69 450001 0
Head of IR & Corporate Communications achim.schreck@flatexdegiro.com
flatexDEGIRO AG
Rotfeder-Ring 7
D-60327 Frankfurt/Main
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenBio AI Builds First World Model of the Human Cell18.8.2026 16:00:00 EEST | Press release
GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by various research labs, AIDO Cell is the first to integrate the entire molecular-to-cellular spectrum into one continuous simulation. Using the system
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 16:00:00 EEST | Press release
Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance. Verified creators, less guesswork. Automated anti-fraud vetting and identity verification at payout means developers partner with rea
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 15:48:00 EEST | Press release
The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCCA) The standout feature of this year’s joint pavilion is its overwhelming genre diversity. The lineup includes roguelike deckbuilders, visual novels, 2D shooters, rhythm action, and cooperative horror survival—catering to a broad spectrum of gamers—alongside immersive content that integrates AI and XR technology. Introducing the Participating T
SLB to Support Offshore Production Restoration for Brunei Shell Petroleum18.8.2026 15:06:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded a contract by Brunei Shell Petroleum (BSP) to support production restoration from shut-in wells across multiple offshore fields. The contract scope spans subsurface evaluation, well candidate selection, engineering and offshore execution. Project management, intervention services, monitoring, metering and marine logistics are integrated within a single coordinated execution model designed to support efficient production restoration. “Building on our long collaboration in the region, this contract reflects a shared commitment to maximizing value from existing offshore resources,” said Gokhan Yarim, senior vice president of Integration, SLB. “Together with BSP, we are combining SLB’s production expertise and integrated execution capabilities to help restore production from shut-in wells, increase recovery from existing infrastructure and support BSP’s long-term production objectives.” The project marks t
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries18.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for the treatment of chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively. Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, exceeding the program’s original scope by approximately 150 patients and helping establish access to innovative cancer care for patients who previo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
